News – Emergent BioSolutions
网页Emergent BioSolutions CEO Robert G. Kramer Appointed to Manufacturers Association Board. Emergent BioSolutions’ president and chief executive officer, Robert G. Kramer, has been named to the National Association of Manufacturers (NAM) Board of Directors. Kramer will join the NAM Board... Read More. January 26, 2021.
Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call …
网页1 天前 · Emergent BioSolutions Inc (NYSE:EBS) resolved a contract dispute with Janssen, resulting in a $50 million settlement payment. The company is expanding NARCAN distribution capabilities with a...
Emergent BioSolutions Awarded $250+ Million in Contract …
网页GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the...
Emergent BioSolutions Announces Strategic Steps to Strengthen …
网页GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services...
Press Releases – Emergent BioSolutions
网页Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG)... Read More
News Release Details - Emergent BioSolutions Inc.
网页GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business. As a result, Emergent is reducing operations at its Bayview facility in Baltimore, Maryland.
Emergent BioSolutions Announces Strategic Operational …
网页2024年5月1日 · Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
News - Emergent BioSolutions Inc.
网页Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
News Release Details - Emergent BioSolutions Inc.
网页GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and profitability of its business.
Emergent BioSolutions Demonstrates Commitment to Increasing …
网页2 天之前 · GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to...